{"entity":{"id":"jennifer-litton","kind":"person","name":"Jennifer K. Litton","aka":[],"tldr":"Jennifer Litton led the EMBRACA trial that brought talazoparib to BRCA-mutated breast cancer.","summary":"Jennifer Litton is Vice President for Clinical Research and Professor of Breast Medical Oncology at MD Anderson Cancer Center. A breast medical oncologist specialising in BRCA and PARP inhibitors, she was principal investigator of EMBRACA, the trial that brought talazoparib to BRCA-mutated breast cancer, and of neoadjuvant talazoparib studies in germline BRCA carriers. Her papers report talazoparib in advanced breast cancer with a germline BRCA mutation in the New England Journal of Medicine and neoadjuvant talazoparib for operable breast cancer with a germline BRCA pathogenic variant in the Journal of Clinical Oncology. She oversees clinical research operations across MD Anderson, with work spanning triple-negative and HR-positive breast cancer and germline testing.","asOf":"2026-09-08","links":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=Jennifer%20K.%20Litton"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Litton%20JK%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Jennifer%20K.%20Litton"}],"tags":[],"related":[],"cancers":["tnbc","breast-hr-positive"],"sections":[],"technologies":["parp-inhibitor","germline-testing"],"targets":["brca","parp"],"drugs":["talazoparib"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Vice President, Clinical Research; Professor of Breast Medical Oncology, MD Anderson","institutionId":"md-anderson","specialisms":["Breast cancer","BRCA","PARP inhibitors"],"profiles":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=Jennifer%20K.%20Litton"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Litton%20JK%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Jennifer%20K.%20Litton"}],"papers":[{"title":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation","journal":"New England Journal of Medicine","year":2018,"url":"https://doi.org/10.1056/NEJMoa1802905","doi":"10.1056/NEJMoa1802905"},{"title":"Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant","journal":"Journal of Clinical Oncology","year":2020,"url":"https://doi.org/10.1200/JCO.19.01304","doi":"10.1200/JCO.19.01304"}],"orcid":"0000-0001-8390-4985"},"route":"/people/jennifer-litton/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"germline-testing","kind":"technology","name":"Germline (hereditary) testing","route":"/technologies/germline-testing/"},{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"}],"target":[{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/"},{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"talazoparib","kind":"drug","name":"Talazoparib","route":"/drugs/talazoparib/"}],"institution":[{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/"}],"roadmap":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/"}],"trial":[{"id":"embraca","kind":"trial","name":"EMBRACA","route":"/trials/embraca/"}]}}